Replies to post #283 on Rezolute Inc. (RZLT)

[rosemountbomber]

One would think that “monumental” data would garner some interest in at least a partner. Of course the doc may have used that term with his company hat on rather than a pure scientist but who knows

[Whalatane]

4th option is to run a larger P2b trial for 6 mths with DME patients confirmed in decline .
Aim would be to see at what pt BCVA ( visual acuity ) improved .
Co maintains 3 mths is to short a time to see improvement in these patients ...but 6 mths on treatment should do it.

Benefit from the injections kicks in fairly fast

anti-VEGF agents like ranibizumab and aflibercept can lead to rapid and significant visual acuity gains in patients with DME, with responses largely established by 3 months of treatmen

Kiwi